EPS: As of FY2025 Q1, the actual value is USD -2.64.

Segment Revenue

• Common Stock Issuance: Heart Test Laboratories, Inc. issued 229,818 shares of Common Stock during the three months ended July 31, 2024, including 14,500 shares under the Equity Line and 120,857 shares under the ATM Facility, receiving net proceeds of approximately $603,746.

Operational Metrics

• Net Loss: The company reported a net loss of $2,051,689 for the three months ended July 31, 2024, compared to a net loss of $1,366,855 for the same period in 2023, representing a 50% increase.
• Operating Expenses: Total operating expenses increased by 56% to $2,075,667 for the three months ended July 31, 2024, from $1,330,655 in the same period in 2023.
• Research and Development Expenses: Increased by 117% to $1,224,931 for the three months ended July 31, 2024, from $565,632 in the same period in 2023.
• Selling, General and Administrative Expenses: Increased by 11% to $850,736 for the three months ended July 31, 2024, from $765,023 in the same period in 2023.

Cash Flow

• Net Cash Used in Operating Activities: The company used $2,018,720 in net cash for operating activities during the three months ended July 31, 2024, compared to $1,404,265 in the same period in 2023.
• Net Cash Provided by Financing Activities: The company generated $551,683 from financing activities during the three months ended July 31, 2024, primarily from the issuance of Common Stock under the Equity Line and ATM Facility.

Future Outlook and Strategy

• Core Business Focus: Heart Test Laboratories, Inc. plans to submit the MyoVista wavECG device for FDA clearance under the 510(k) pathway in the first calendar quarter of 2025, aiming to market and sell the device in the U.S. upon successful clearance.
• Non-Core Business: The company is developing the MyoVista Insights Cloud Platform to host AI-ECG algorithms and plans to submit it for FDA clearance in mid-2025.